First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

BACKGROUND: Platinum‐based chemotherapy remains a first‐line standard of care for approximately 30% of patients with non‐small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab‐paclitaxel/carboplatin (nab‐P/C) combination was shown in the pivotal...

Descripción completa

Detalles Bibliográficos
Autores principales: Dechow, Tobias, Riera‐Knorrenschild, Jorge, Hackanson, Björn, Janssen, Jan, Schulz, Holger, Chiabudini, Marco, Fischer von Weikersthal, Ludwig, Budweiser, Stephan, Nacke, Axel, Taeuscher, Dagmar, Welslau, Manfred, Potthoff, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607256/
https://www.ncbi.nlm.nih.gov/pubmed/34668662
http://dx.doi.org/10.1002/cam4.4310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607256/
https://www.ncbi.nlm.nih.gov/pubmed/34668662
http://dx.doi.org/10.1002/cam4.4310

Ejemplares similares